viernes, 12 de enero de 2018

Living Longer With Cystic Fibrosis - Ivanhoe Broadcast News, Inc.

Living Longer With Cystic Fibrosis - Ivanhoe Broadcast News, Inc.


CLEVELAND, Ohio. (Ivanhoe Newswire) — More than 30,000 Americans are living with cystic fibrosis, or CF, for short. Years ago most kids with this disease didn’t make it into their teens, but now, more and more are living longer.

CHICAGO, Ill. (Ivanhoe Newswire) — One in 133 Americans have celiac disease, although experts say many haven’t been diagnosed. People with celiac disease have a reaction to gluten, which is present in anything made with wheat, rye, or barley. Researchers say they have found a potential cause for the condition, which brings them closer to a cure.

ORLANDO, Fla. (Ivanhoe Newswire) — Crohn’s disease is a chronic inflammatory bowel disease of the digestive, or, GI tract. It causes inflammation, which can lead to abdominal pain, severe diarrhea, weight loss and fatigue. It is often misdiagnosed for ulcerative colitis, or, IBS. Discover fact from fiction when it comes to diagnosing Crohn’s disease.

ORLANDO, Fla. (Ivanhoe Newswire) — Caffeine consumed too late in the day may disturb your sleep which could ultimately lead to harming your brain. But your morning cup of coffee contains the chemical EHT, which has been shown to help protect against Alzheimer’s disease.

PORTLAND, Ore. (Ivanhoe Newswire) — Nearly 800,000 people have strokes every year in America. The best treatment, tPA (tissue plasminogen activator), has to be given within three hours, and doctors estimate only five percent of patients can make that window. A new treatment that is now in clinical trial could give patients precious additional time.

Quote of the week:
Give people what they need: food, medicine, clean air, pure water, trees and grass, pleasant homes to live in, some hours of work, more hours of leisure. Don’t ask who deserves it. Every human being deserves it.” 
— Howard Zinn

Give the gift of health news!
Click here to sign up your friends and loved ones for the 

First to Know Newsletter!

Website Information:

Content Licensing:

No hay comentarios:

Publicar un comentario